Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This
clinical study is designed to test the hypothesis that lurasidone is effective, tolerable,
and safe as compared with quetiapine XR short term among acutely psychotic patients with
chronic schizophrenia.